MedBulletinsAura Celeste
Infectious diseases

Monthly infectious diseases bulletin — November 15, 2026

🎧 Listen to this issueAudio newscast · 6:25 min

This issue covers October 16 to November 15, 2026, starting the day after the previous issue. The month was shaped by IDWeek 2026 (Washington, DC, October 21–24), with data on Staphylococcus aureus bacteremia, febrile neutropenia, and a new oral antifungal for aspergillosis; by the first FDA approval of an antisense oligonucleotide for chronic hepatitis B; by the first generic lenacapavir for preexposure prophylaxis in low- and middle-income countries; and by the CDC's new antimicrobial resistance threats report. On the surveillance side, Bundibugyo Ebola has now passed 10,000 confirmed cases and measles remains active in the Americas. Several IDWeek data sets are preliminary or come from posters without peer review; when their results come from specialist press coverage, we attribute them in each item.

1. Antimicrobials and resistance

1. CDC: new antimicrobial resistance threats report estimates over 9.3 million drug-resistant infections a year

[Publication] [United States]
On October 27, the CDC released an update of its antimicrobial resistance threats report using 2023 data, the first since the 2019 report. CDC estimates over 9.3 million drug-resistant infections and over 39,000 deaths annually in the United States. Including C. difficile raises the report's total to 9.7 million infections and 50,800 deaths; these totals are not restricted to drug-resistant infections. The 2019 report estimated about 2.8 million resistant infections and 35,000 deaths, excluding C. difficile, which it reported separately. Candida auris reached 4,523 clinical cases in 2023, nearly ten times the 2019 count. In 2023, an estimated 14,878 cases of carbapenem-resistant Enterobacterales occurred in hospitalized patients in the United States, with 1,252 deaths attributable to these infections. The four "urgent" threats are C. auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, and drug-resistant Neisseria gonorrhoeae. Clostridioides difficile was downgraded from "urgent" to "serious." Drug-resistant N. meningitidis was added as a "serious" threat.
Why it matters: the CDC itself notes that methods and data sources changed between reports, so their totals should not be compared directly. Surveillance for C. auris and carbapenemases, supported by laboratory identification, remains relevant to hospital prevention.

Sources

2. Brazil: Anvisa opens its 2026 national assessment of antimicrobial stewardship programs

[Regulatory ANVISA] [Brazil]
On October 23, Anvisa launched the 2026 National Assessment of Hospital Antimicrobial Stewardship Programs, open to public, private, philanthropic, and military hospitals until December 20. In the 2024 round, 1,453 hospitals took part and just over half reported having a program in place. The main barriers were institutional support, integration across services, and staff technical training.
Why it matters: this is a self-reported survey, not a clinical study, but it offers a national measurement of stewardship programs that could serve as a model for other countries in the region.

Sources

3. Post-exposure oseltamivir: small trial compares five versus ten days in hospitalized adults

[Congress] [Slovenia]
According to Contagion Live's coverage of poster P-216 presented at IDWeek 2026, this randomized open-label study from University Medical Center Ljubljana enrolled 166 hospitalized adults with influenza exposure, median age 78.5 years, with high comorbidity (median Charlson index 6). Influenza developed in 0 of 82 in the 5-day group and 1 of 84 (1.2%) in the 10-day group (difference 1.2 percentage points; 95% CI −1.15 to 3.55). There were no serious adverse events related to oseltamivir.
Why it matters: it could support shorter prophylaxis during nosocomial influenza outbreaks and saves antivirals, but these are meeting data known through press coverage, from a single center, open-label, with very few events and limited power to show noninferiority; this result alone does not establish clinical equivalence or justify a protocol change, and full publication should be awaited.

Sources

2. HIV, viral hepatitis, and STIs

4. FDA approves bepirovirsen (Hibsago), the first antisense therapy for chronic hepatitis B

[Regulatory FDA] [United States / multinational]
On October 20, the FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on a nucleos(t)ide analogue for at least six months, without cirrhosis, with suppressed viral load and HBsAg ≤3,000 IU/mL. Approval rests on the phase 3 B-Well 1 and B-Well 2 trials (randomized, double-blind, placebo-controlled, 29 countries): functional cure was 19% (233/1,220) with bepirovirsen versus 0% (0/614) with placebo, and 26% (200/768) among those with baseline HBsAg ≤1,000 IU/mL. Dosing is 300 mg subcutaneously once weekly for up to 24 weeks, added to the existing nucleos(t)ide analogue, which continues for at least another 24 weeks after the last injection; only patients meeting clinical and laboratory stopping criteria may discontinue it afterward. Functional cure (undetectable HBV DNA and HBsAg) was assessed at least 24 weeks after all treatment ended. The label carries a boxed warning for serious liver reactions and thrombocytopenia, and FDA requires monitoring before and during treatment.
Why it matters: it is a finite-duration therapy that, added to antiviral treatment, achieves functional cure in a meaningful share of patients, but four in five do not reach it, the trials were manufacturer-funded, and the benefit concentrates in patients with low HBsAg; quantitative HBsAg will be essential, and cost and availability in the Caribbean remain unknown.

Sources

5. First generic lenacapavir for PrEP: FDA tentative approval for 120 countries

[Regulatory FDA] [India / low- and middle-income countries]
The FDA granted tentative approval to Dr. Reddy's generic twice-yearly injectable lenacapavir, announced by Unitaid on November 2. Tentative approval does not allow US sales but makes the product eligible for US government procurement. It is intended for the 120 low- and middle-income countries in Gilead's voluntary licensing program, at about $40 per person per year, versus a US list price of $28,218 for the originator. First supplies are expected by the end of 2026.
Why it matters: the target price lowers a major barrier, but experts warn that it is not enough without services able to reach and retain people. The Dominican Republic is among the 120 countries covered by the voluntary license. This does not establish local regulatory approval or availability; supply planning and follow-up services are still needed.

Sources

6. PURPOSE 5: twice-yearly lenacapavir nearly doubles PrEP persistence versus the daily pill

[Congress] [United Kingdom and France]
Data from the phase 2, randomized (2:1), open-label PURPOSE 5 study, presented at HIV Glasgow 2026 and released by Gilead on November 6. The study enrolled 267 people not on PrEP at entry. At week 52, 85.6% (154/180) on lenacapavir versus 46.3% (37/80) on daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) met the persistence definition (difference 39.3 percentage points; p<0.0001). Protocol-defined persistence required on-time injections and follow-up for lenacapavir, versus tenofovir levels consistent with at least four weekly doses at four visits for F/TDF. The open-label design and different measurements limit interpretation. There were no HIV acquisitions with lenacapavir and one with oral PrEP, with drug levels consistent with fewer than two doses per week.
Why it matters: in Europe, the injectable showed greater persistence under these definitions; on its own this does not estimate superiority for HIV prevention, and the study is open-label, small, ongoing, and reported by the manufacturer.

Sources

7. Zoliflodacin in gonorrhea with chlamydia coinfection: subgroup analysis presented at IDWeek

[Congress] [International]
Subgroup analysis of the phase 3 trial (randomized 2:1, open-label, noninferiority) presented at IDWeek on October 24. Of 923 participants tested for chlamydia, 235 (25%) were coinfected with Chlamydia trachomatis. As background, the phase 3 trial, published in The Lancet in January 2026, reported overall urogenital microbiological cure of 90.9% (460/506) with oral zoliflodacin versus 96.2% (229/238) with ceftriaxone 500 mg plus azithromycin. IDWeek coverage attributes similar results with and without chlamydia to the authors but gives no subgroup rates.
Why it matters: the message is reassuring for a very common clinical scenario, but it comes from a subgroup analysis without published rates; zoliflodacin does not replace specific treatment for chlamydia.

Sources

3. Healthcare-associated infections, immunocompromised hosts, and transplantation

8. SABEDTIO: early dual therapy shortens persistent S. aureus bacteremia

[Congress] [United States]
According to Contagion Live and Healio coverage of the abstract presented at IDWeek 2026, these are preliminary data from a pragmatic, open-label, 2:1 randomized trial (NCT07148960) at six hospitals in a rural health system. With 193 patients enrolled (target 300) and 152 with complete follow-up, upfront dual IV therapy (daptomycin plus ceftaroline, or cefazolin plus ertapenem), with oral step-down after negative blood cultures at 72 hours, reduced prolonged bacteremia (≥6 days) from 16% to 6% (P = .05). Observed mortality was about 20% in each arm; these preliminary data do not establish equivalence.
Why it matters: this is an interim, open-label result known through press coverage, from a single health system with a borderline P value; no mortality difference was observed and the primary composite outcome is not yet known, so it does not yet justify routine dual therapy.

Sources

9. END trial: stopping empiric antibiotics early in high-risk febrile neutropenia

[Congress] [United States]
According to Contagion Live's coverage of poster P-213 presented at IDWeek 2026, this is an interim analysis of a phase 4, 1:1 randomized, open-label, single-center trial that enrolled 157 adults with hematologic malignancies and high-risk febrile neutropenia without an identified bacterial source (148 completed follow-up), randomized after 48 hours afebrile to stop antibiotics or continue them until count recovery. Observed severe-event rates by day 60 (death, septic shock, or ICU transfer) in this interim analysis were 11.0% versus 13.3%; this does not establish equivalent safety. Antibiotic-free days during neutropenia rose from 3.8 to 10.5, with no difference in length of stay (median 25 days in both arms).
Why it matters: it supports the ECIL approach of de-escalating in neutropenia without a source, with large antibiotic savings, but it is an interim, single-center analysis known through press coverage, without power to prove safety; applying it requires close monitoring that not every service can guarantee.

Sources

10. OASIS: oral olorofim noninferior to liposomal amphotericin B in difficult invasive aspergillosis

[Congress] [International]
International phase 3, 2:1 randomized, adjudicator-blinded trial (NCT05101187), presented as a late-breaker at IDWeek on October 22. The study randomized 225 adults at 140 sites with proven invasive aspergillosis or probable pulmonary invasive aspergillosis for whom a mold-active azole was inappropriate (resistance, breakthrough on prophylaxis, interactions) or had failed. Day-42 all-cause mortality was 23.8% (36/151) with oral olorofim versus 24.3% (18/74) with liposomal amphotericin B followed by standard care (difference −0.5%; 95% CI −13.1 to 10.8; 20% noninferiority margin).
Why it matters: it is an oral antifungal from a new class (the orotomides) with phase 3 data in patients for whom azoles are not an option; however, the 20% margin is wide, the study is sponsored by F2G and Shionogi, and these are meeting data for a drug that is not yet approved.

Sources

4. Vaccines, arboviruses, tropical and emerging diseases

11. Bundibugyo Ebola: nearly 11,000 confirmed cases in the DRC and an imported case in Nigeria

[Publication] [Central and West Africa]
According to the ECDC update of November 10, the Democratic Republic of the Congo has 10,990 confirmed cases and 5,354 deaths (data through November 8) across eight provinces. Kenya has 9 cases and 2 deaths; its last confirmed case was reported on October 20. On October 20, Nigeria confirmed an imported case in a woman who had traveled from Uganda and sought care in Abuja; she was medically evacuated on October 26 to Geneva University Hospitals. The phase 2/3 Tumaini trial of vaccine candidates began in Bunia on October 23.
Why it matters: only 79.2% of identified contacts were under follow-up in the affected provinces and clusters of community deaths have been reported, which suggests late detection; there is no licensed vaccine or treatment for this species, so febrile-traveler protocols for arrivals from Africa should be current in our hospitals too.

Sources

12. Measles in the Americas: 57,666 confirmed cases in 2026, 4.7 times more than in the same period of 2025

[Publication] [Americas]
PAHO situation report no. 15 (November 5, data for epidemiological weeks 1 to 43) counts 57,666 confirmed cases in 17 countries and territories and 81 deaths (53 in Guatemala, 23 in Mexico, 3 in the United States, and 1 each in Peru and Bolivia). Guatemala (34,748), Mexico (13,761), the United States (4,852), Peru (2,862), and Canada (1,126) account for 99.5% of cases. In weeks 41 and 42, 547 new cases were reported in six countries, 38% fewer than in the previous two weeks.
Why it matters: the recent slowdown is encouraging, but transmission persists and the report itself warns of reporting delays and retrospective notification, so the decline in recent weeks should be read with caution; any febrile rash in travelers from areas with transmission should prompt isolation and notification, and two-dose coverage among healthcare workers should be checked.

Sources

13. PAHO calls for stronger surveillance as dengue and chikungunya rise in the Caribbean and Andes

[Publication] [Americas]
In its October 20 epidemiological update and October 21 statement, PAHO reported 1.69 million suspected dengue cases through mid-September, 58% fewer than in the same period of 2025, with 3,413 severe cases and 571 deaths, though with recent increases in the Andean, Central American, and Caribbean subregions; the update names Colombia, Costa Rica, Cuba, Ecuador, El Salvador, Honduras, Mexico, Panama, and Peru among them. All four serotypes are circulating in the region as a whole. There were 213,919 suspected chikungunya cases, 78,481 confirmed, and 88 deaths in 20 countries and territories, with resurgence where the virus had not circulated for years. PAHO warns of the anticipated intensification of El Niño and the start of South America's peak season.
Why it matters: the regional decline may create false reassurance; with four serotypes circulating in the region and chikungunya expanding, emergency departments must recognize dengue warning signs early and avoid confusing the two.

Sources

14. South Africa: clade Ib mpox rising, with 26 cases in 2026

[Publication] [South Africa]
According to Spotlight (Daily Maverick, November 3), using National Institute for Communicable Diseases (NICD) data with an October 27 cutoff, South Africa had 26 confirmed mpox cases in 2026, 20 of them since August. Nineteen are subclade Ib, four IIb, and three untyped; 18 are in the Western Cape, and all but one are men aged 23 to 50. Seven were hospitalized and none died. Two cases had recent travel to Spain and Belgium, and two others arrived already infected. A total of 3,865 MVA-BN doses remain, expiring on August 31, 2027.
Why it matters: the article infers local transmission of clade Ib outside Central Africa, among young adults; this is a press report based on the NICD dashboard, but it confirms that mpox surveillance should include clade sequencing.

Sources

Upcoming meetings and dates

  • World AMR Awareness Week: November 18–24, 2026.
  • World AIDS Day: December 1, 2026.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.